# Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct03018028` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03018028](<https://clinicaltrials.gov/study/NCT03018028>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03018028

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.

## Technical summary

Registry record NCT03018028. Randomized; double masking; primary purpose treatment. Start 2017-01-10 (actual); primary completion 2018-01-09 (actual). Results posted on 2019-12-30.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 243 participants (enrolled count; ClinicalTrials.gov record NCT03018028, source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)
- Started: 2017-01-10 (actual) (ClinicalTrials.gov record NCT03018028, source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)
- Primary completion: 2018-01-09 (actual) (ClinicalTrials.gov record NCT03018028, source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)
- Completion: 2018-08-15 (actual) (ClinicalTrials.gov record NCT03018028, source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)
- Results first posted: 2019-12-30 (ClinicalTrials.gov record NCT03018028, source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03018028, source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03018028-2021-01-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
- Acronym: PIONEER 9
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Intervention (Drug): Liraglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial (`cardio:pubmed-32333875`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8bc592c07e0f950fcf9a40ee95efc27f5cb19e894e18e4d1d33eb1b6c60b6abc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
